Video Gallery

At the Veeva R&D and Quality Summit in Boston, Moe Alsumidaie interviewed Jeff Sorenson, CEO of Yunu, and Steve Tolle, Chief Product & Technology Officer at Ignitedata, on how the updated ICH E6(R3) guidance is transforming imaging in clinical trials.

Paul J. McCracken, Ph.D. from RadiaNova Consulting, LLC put it bluntly: If imaging isn’t baked into your protocol design — your timing, equipment specs, and site readiness — you’re already behind.

Paul J. McCracken, Ph.D., founder of RadiaNova Consulting, LLC, pointed out one of the biggest blind spots in clinical trial imaging — and it’s not about technology.

At DPHARM, Paul McCracken, Founder and Principal of RadiaNova Consulting, sheds light on the hidden challenges of clinical trial imaging and how radiopharmaceutical studies are transforming its role.

Yunu CTO & Co-Founder Gael Kuhn explains Yunu's unique advantage in its team and tech.

Yunu CTO & Co-Founder Gael Kuhn explains Yunu's approach to innovation.

CEO & Co-Founder Jeff Sorenson explains what Yunu can do for radiologists.

CEO & Co-Founder Jeff Sorenson explains what Yunu can do for Cancer Centers.

Yunu helps sponsors achieve diverse and inclusive trials by providing access to populations who were previously limited by the geographic challenges of trial imaging.

Yunu CSO & Co-Founder Dr. Gordon Harris shares how the proliferation of Yunu has transformed cancer centers' clinical trial operations.

Yunu CSO & Co-Founder Dr. Gordon Harris explains Yunu's impaction on patients and trial enrollment.

Yunu CSO & Co-Founder Dr. Gordon Harris shares Yunu's history in academic roots and with industry innovators.

What challenges are faced by imaging providers that want to participate in oncology clinical trials? Hear about the problems -- and solutions -- with Yunu co-founders Jeffrey Sorenson and Gordon Harris during this interview with The Imaging Wire's Brian Casey at the JP Morgan Health Care Conference and Biotech Showcase.